Alliança Saúde e Participações S A : 4Q23 Earnings Presentation

EARNINGS RELEASE

4Q23 / 2023

LEGAL DISCLOSURE

This presentation may contain certain forward-looking statements and information relating to Alliança Saúde e Participações S.A. (Alliança) and its subsidiaries, which reflect the Company's current views and/or expectations regarding its business performance and future events. Forward-looking statements include, without limitation, any statement that may predict, predict, indicate or imply future results, performance or achievements, and may contain words such as "believes," "anticipates," "expects," "estimates," "could," "predicts," "potential," "likely outcome" or other words or expressions of similar meaning.

Such statements are subject to a number of risks, uncertainties and assumptions. Please be advised that several important factors may cause actual results to differ, any third parties (including investors) are solely and exclusively liable for any investment or business decision or action taken in reliance on the information and statements contained in this presentation or for any consequential, special or similar damages.

Alliança undertakes no obligation to update or revise this presentation in light of new information and/or future events. In addition to the factors identified elsewhere in this presentation, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: changes in our consumers' financial preferences and conditions and competitive conditions in the markets in which we operate, changes in economic, political and business conditions in Brazil; government interventions, resulting in changes in the Brazilian economy, taxes, tariffs, or regulatory environment, our ability to compete successfully; changes in our business, our ability to successfully implement marketing strategies; our identification of business opportunities, our ability to develop and introduce new products and services, changes in the cost of products and operating costs; our level of indebtedness and other financial obligations, our ability to attract new customers; inflation in Brazil, depreciation of the real against the U.S. dollar and interest rate fluctuations, present or future changes in laws and regulations, and our ability to maintain existing business relationships and create new ones.

2

OPERATIONAL PERFORMANCE AND STRATEGIC POSITIONING

Consecutive growth in 4Q23 and 2023

Revenue and EBITDA grow for another quarter

BRL 1,3 bn

Gross Revenue1 2023

		Revenue on the Rise
		+6%				+8%
		299				1,256
281	1,167

4Q22

4Q23

2022

2023

• Gross operating income excludes "construction revenue".

BRL 235 mn

Adjusted EBITDA 2023

Highest Historical Evolution of
	+84%	EBITDA	+29%
			235
	47
			183
26

4Q22

4Q23

2022

2023

20%

Adjusted EBITDA Margin 2023

Progression in Profitability in Q4

6.8 p.p.	3.2 p.p.
17%	20%
	17%
10%

4Q22 4Q23 2022 2023

	4
Send your questions during the event through the chat, or by WhatsApp: [phone]

4Q23 and 2023 Highlights

Productivity

Revenue Growth in Diagnostic Imaging (R$ mi)

	7%	11%
252	269	1,014	1,121

Alliances and Expansions

Asset Light Strategies

• Support laboratory of the onco-hematology clinic;
• Outsourcing of anatomical pathology exams;
• Partnership for Exams of Technological Solutions.

Management Agreement and M&A Potential

• Operational partnership with Fonte da Saúde Fund in relation to the units owned by ProEcho with potential for future M&A;
• Execution of an exclusivity agreement for the future acquisition of CEPEM, with expansion in diagnostic services for Women's Health.

4Q22 4Q232022 2023

Commercial Positioning

YoY Average Ticket Variance (%)

	MRI	US	CT	CA
	(Ex-Covid)
4Q22 vs. 4Q23	3.0%	6.2%	8.7%	10.8%
2022 vs. 2023	4.1%	6.7%	13.7%	11.6%

Organic and Non-Organic Growth

• JV with Unimed Nacional, working to create the first Operational Technical Center in the metropolitan region of Salvador;
• 30-yearconcession (PPP) for the operation of the Regional Urgency and Emergency Hospital of Rondônia.

Incorporation

• Merger of subsidiaries, Delfin Clinic for consolidation and integration of assets into the Company's corporate and operational structures.

	5
Send your questions during the event through the chat, or by WhatsApp: [phone]

FINANCIAL PERFORMANCE

GROSS REVENUE BREAKDOWN

Evolution of Gross Revenue1 in the period

(BRL mn)

	+6%	+8%
281	299	1,256
	1,167

Evolution of Gross Revenue1

(BRL mn)

	315				+6%
				299
283		290
20%	281
10%
% CA 13%	15%	11%

% Imaging 87%	80%	85%	89%	90%

4Q22

4Q23

2022

2023

4Q19

4Q20

4Q21

4Q22

4Q23

• Gross operating income excludes "construction revenue".

	7
Send your questions during the event through the chat, or by WhatsApp: [phone]

GROSS REVENUE BREAKDOWN

Gross Revenue1

(BRL mn)

+8%

Imaging Exams Revenue

(BRL mn) +11%

Variation

(4Q23 vs. 4Q22)

1,167

1,256

1,121

1,014

Resonance Magnetic (MRI)

	Share of	Variation
	Revenue	Average Ticket
3%	36%	+3.0%

MRI 417

454

Imaging Exams (ex-MRI)

10%

54%

n/a

Others 597 667

2022

2023

2022

2023

• Gross operating income excludes "construction revenue".

Clinics

Analysis

Total Revenue

1%	10%	+9.3%
6%	100%

	8
Send your questions during the event through the chat, or by WhatsApp: [phone]

COSTS AND EXPENSES

								% of Adjusted ROL	Non-Recurring
33%	35%
		406							26%
		21%							23%
		18	20%
358
23				13%
					10%	11%	10%	283	265
				239			31
			229					30
335	388
			139	117	118	113
					252
			229	239		235
					139	117	118	113
2022	2023	2022	2023	2022	2023	2022	2023	2022	2023
	Personal	Medical Services	Supplies and Support	Depreciation and	3rd-Party Services
1 Others = Maintenance Costs, Occupancy, Long-Term Incentive Program and Others		Labs	Amortization	and Others1

	9
Send your questions during the event through the chat, or by WhatsApp: [phone]

ADJUSTED EBITDA

Positive impact on margin and EBITDA growth higher than in recent years

YoY Variation

Adjusted EBITDA1 in the period

Fiscal Year Ended

								84%
					24%	12%		25%
				-20%
	-29%	-22%	-43%
-58%
	51	59	47		63	66	58	47
32
			26
4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23

1Adjustments ref. to the recovery of investments made by RBD in the public-private partnership with the State of Bahia and to non-recurring expenses.

	10
Send your questions during the event through the chat, or by WhatsApp: [phone]